- QLT REPORTS POSITIVE PRELIMINARY RESULTS FROM PHASE Ib RETREATMENT TRIAL OF QLT091001. QLT Inc.
announced positive preliminary results from its international, multicenter, open-label Phase Ib clinical trial of repeated treatments of oral QLT091001 in subjects with Leber's congenital amaurosis (LCA) or retinitis pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT). The proof-of-concept trial was an extension study in which LCA or RP subjects with RPE65 or LRAT mutations who had been previously treated with a single course of QLT091001 in the company's previously completed Phase Ib study, received up to three seven-day courses of QLT091001 to assess visual outcomes and safety following retreatment. Preliminary results of the study show clinically meaningful improvements in visual fields (VF) and visual acuity (VA). To date, 19 of 27 subjects (70%) had an increase in VF retinal area from baseline of ≥ 20% in at least one eye at two consecutive visits within six months from the start of any QLT091001 treatment course. Plus, 70% of subjects had an increase in VA from baseline of five or more letters in at least one eye at two consecutive visits within six months from the start of any treatment course. The final clinical data, including the duration of response and other evaluations, are anticipated for release in the third quarter of 2014.
- ENROLLMENT BEGINS IN WET AMD STUDY. In 2013, Moorfields and SalutarisMD announced their collaboration to advance the research and development of a novel medical device for use in the treatment of wet age-related macular degeneration (AMD). Now, enrollment has begun in a Salutaris Medical Devices Ltd.-sponsored observational study (“A Prospective Study to Determine Choroidal and Scleral Depth in Subjects with Neovascular Age-related Macular Degeneration Receiving Anti-VEGF Therapy”) conducted at Moorfields Eye Hospital NHS Foundation Trust to accurately measure the scleral and choroid thickness at the fovea and at the choroidal neovascular lesion. The SalutarisMD device employs a minimally invasive retrobulbar episcleral brachytherapy application to the neovascular membranes. The study will use three imaging modalities to determine the depth from the retrobulbar episcleral surface to the vitreous side of the sclera, choroid, and retina at the center of the fovea and choroidal neovascularization. Enrollment of study subjects is ongoing. Read more at
- STUDY RESULTS SUPPORT ADDITIONAL MECHANISM OF ACTION FOR LEAD GLAUCOMA DRUG CANDIDATE AR-13324. Aerie Pharmaceuticals Inc. recently announced results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure (EVP) in the eye. The drops previously have been shown to lower intraocular pressure (IOP) by increasing fluid outflow through the trabecular pathway, the eye's primary drain, and by reducing the production of fluid in the eye. The present study affirmed the hypothesis that AR-13324 can also lower IOP through a third mechanism of action, the reduction of EVP, which may represent a breakthrough in the lowering of IOP in patients with glaucoma and ocular hypertension. According to the study results, administration of AR-13324 eye drops once daily demonstrated statistically significant reductions in EVP and IOP in an in vivo model following the third daily dose. EVP decreased by 35% relative to baseline, and IOP was reduced by 39%. Based on these results, the researchers estimated that up to 42% of the reduction in IOP caused by AR-13324 was due to the reduction in EVP. For additional details, click
- FDA GRANTS CLEARANCE FOR VICTUS FEMTOSECOND LASER PLATFORM. Bauch + Lomb's Victus Femtosecond Laser Platform has received 510(k) clearance from the FDA for the creation of cuts/incisions in the cornea of patients undergoing cataract surgery or other ophthalmic treatment requiring cuts/incisions in the cornea. The Victus Femtosecond Laser Platform is designed to support a comprehensive suite of cataract and corneal procedures in a single instrument. This new indication will function in concert with existing advanced proprietary features including an easy-to-use patient interface and real-time OCT imaging to optimize each cataract procedure being performed. Find out more about the Victus Femtosecond Laser Platform at
- TOPCON LAUNCHES KR-800S AUTO REFRACTOR WITH SUBJECTIVE TESTING. Topcon Medical Systems has released its KR-800S Auto Kerato-Refractometer with Subjective and Glare Testing. The new five-in-one instrument features the latest in autorefraction technology, incorporating Topcon's Rotary Prism technology for unparalleled accuracy and consistent measurements. It adds on Subjective Visual Acuity testing, allowing you to refine a patient's measurements. The KR-800S features several new tests, including a visual acuity check for near and far distance, a contrast sensitivity test, a grid test and glare testing. It also features a compact and user-friendly design with an 8.5” color touchscreen display that provides quick and accurate readings with minimal training required. For more information, visit
- FIRST ANNUAL CURE BLINDNESS VALDEZ CHARITY FUNDRAISER TO TAKE PLACE. ManagementPlus Inc. recently announced its central role as organizer and contributor to the first annual Cure Blindness Valdez charity fundraising event, to be held April 27 through May 3, 2014, in Valdez, Alaska. The event has a fundraising goal of $110,000 and will be led by ManagementPlus chairman Mark Archibald, and hosted by Geoff Tabin, MD, co-founder of the Himalayan Cataract Project. The fundraiser will bring together business leaders, champion skiers and philanthropists for one week of heli-skiing to raise money for construction of a permanent primary eye-care facility in Manang, a village in central Nepal that serves as a central hub for several important land routes.
- ZEISS PROGRESSIVE CHOICE PLUS SPORT LENSES INTRODUCED. Zeiss has extended its line of Zeiss Progressive Choice lenses with the addition of Zeiss Progressive Choice Plus Sport, a lens specifically designed for wrap frames. According to the company, the Choice Plus Sport design combines advanced customization for the patient's full prescription with proprietary Zeiss prism compensation. This combination widens the area of clear vision by as much as 50% over standard lens designs in wrap frames, while dramatically reducing unwanted prism. The lenses are available in two corridor lengths, with minimum fitting heights of 13mm and 17mm. Zeiss Progressive Choice Plus Sport lenses are fully compatible with i.Scription by Zeiss and are available in 1.50 Hard Resin, 1.53 Trivex and 1.59 polycarbonate, with polarized options in all materials. Additionally, they are available with PhotoFusion by Zeiss and various NXT treatments.
- OWL HOSTS ANNUAL AWARDS RECEPTION AT ASCRS. Ophthalmic Women Leaders (OWL) will be hosting its annual awards reception honoring influential women within ophthalmology. The reception will be held Monday, April 28 from 5:30 p.m. to 7:00 p.m. during the 2014 American Society of Cataract & Refractive Surgeons Meeting in Boston. Three awards will be presented at the reception: the Vision Woman Award, the Catalyst Award and the Rising Star Award. Nominations will be accepted
online through March 14, 2014. OWL members are invited to nominate one or more individuals for each of the awards; nominees are not required to be OWL members. Voting by OWL members for each award will take place from March 19 through April 4, 2014 through
www.owlsite.org. Winners will be honored on April 28, 2014 at the annual ASCRS OWL event. Admission to the reception is free for OWL members and $25 for non-members.